|Moonshot for precision medicine|
Journal of Immunotherapy and Precision Oncology 2019 2(2):21-22
|Tackling immunotherapy resistance: Developing rational combinations of immunotherapy and targeted drugs|
Elena Cojocaru, Mariana Scaranti, Anna Minchom
Journal of Immunotherapy and Precision Oncology 2019 2(2):23-35
Mechanisms of resistance to immunotherapies are multiple and complex with components intrinsic to the tumor cell and within the immune microenvironment. We review evidence of the interaction of tumor cell signaling pathways with immune pathways and the role this plays in de novo and acquired resistance. The mitogen-activated protein kinase (MAPK) pathway activation and effects on T-cell function are discussed. Phosphoinositide 3-kinase (PI3K) pathway activation (including PTEN loss of function) correlates with T-cell inhibition and immunotherapy resistance. Wnt signaling has been implicated in T-cell function suppression. Key evidence from preclinical models exists for the role of these signaling pathways and is described. Clinical evidence is less advanced though correlation of mutations in key nodes with immune resistance provides a limited clinical correlation. Serial biomarker analysis in patients receiving targeted drugs has been attempted with notable examples including BRAF inhibition in melanoma patients resulting in dynamic changes in programmed death-ligand 1 (PD-L1) expression and tumor-infiltrating lymphocytes. Drug combinations aim to overcome mechanisms of resistance, and recent years have seen numerous combinations of targeted therapies and immune checkpoint inhibitors proposed. However, clear biological rationale and thoughtful trial designs with a translational focus are required to allow such combinations to achieve their full potential.
|Should we design clinical trials differently in the era of cancer immunotherapy?|
Journal of Immunotherapy and Precision Oncology 2019 2(2):36-39
The oncology clinical trials are evolving in the era of cancer immunotherapy. In Phase I trials, some severe immune-related adverse events occur beyond the first cycle. This is important to determine the recommended Phase II dose if the treatment duration is long. If there is no dose–response/toxicity relationship, it will not be necessary to push to the maximum tolerated dose. In Phase II trials, companion predictive biomarkers are valuable in cancers with intermediate response rates. Randomized (comparison, selection, or discontinuation) Phase II trials are needed in cancer immunotherapy combination. In Phase III trials, milestone analysis and restricted mean survival time could serve as the alternatives to hazard ratio to fit the survival kinetics of cancer immunotherapy.
|Vedolizumab Achieved Clinical and Histologic Remission in a Patient with Lung Cancer Who Had a Steroid-Refractory Upper Gastrointestinal Injury Due to Nivolumab Treatment|
Cynthia Nguyen Tran, Hamzah Abu-Sbeih, Wenyi Luo, Yang Lu, Yinghong Wang
Journal of Immunotherapy and Precision Oncology 2019 2(2):40-45
Immune checkpoint inhibitors (ICIs) have emerged as a novel therapeutic class for various malignancies. Their immune upregulation promotes significant anti-tumor effect, but simultaneously, can also result in treatment-limiting immune-related adverse events (irAEs). The data on upper gastrointestinal (GI) tract irAEs are sparse. We herein describe a case of steroid-dependent upper GI toxicity with nivolumab (an anti-programmed death [PD] protein-1) that achieved clinical and histological remission with vedolizumab treatment (a GI tract targeted anti-integrin antibody). A 65-year-old male patient with progressive lung cancer was treated with nivolumab and following 16 cycles, developed severe nausea, vomiting, and epigastric abdominal cramps requiring five hospitalizations. His initial esophagogastroduodenoscopy (EGD) showed active inflammation in both the stomach and duodenum. Nivolumab was discontinued, but despite treatment with multiple steroid courses, his symptoms always recurred during prednisone taper. Clinical remission was ultimately achieved with vedolizumab. His last EGD after five infusions of vedolizumab demonstrated resolution of inflammation. His lung cancer has since relapsed and the treatment plan was to resume nivolumab concurrently with vedolizumab. In conclusion, ICIs, such as nivolumab, have emerged as therapy for various malignancies. Their use can be associated with various irAEs including the upper GI adverse events which is uncommon. This case scenario showed that vedolizumab can provide a steroid-sparing therapeutic effect to achieve remission of upper GI irAEs even in cases where multiple steroid courses have failed.
|5th Annual immuno-oncology 360° conference: Spanning science and business to bring new therapies to patients|
Journal of Immunotherapy and Precision Oncology 2019 2(2):46-51
Otology & Neurotology - Papers Presented at the Annual Meeting of the German Audiology and Neurotology Group 2015 (ADANO) in BernOcular Vestibular Evoked Myogenic Potentials: Where Are We Now? Objective: Over the last decade, ocular vestibular evoked myogenic potential...
Otology & Neurotology - Highlights from the ACIA 15th Symposium on Cochlear Implants in Children in San FranciscoIntroduction to the Special Issue: 15th Symposium on Cochlear Implants in Children No abstract available Relationship Between Objective and ...
Otology & Neurotology - Papers Presented at the Annual Meeting of the German Audiology and Neurotology Group 2014 (ADANO) in DresdenSpecial Issue for Papers Presented at the Annual Meeting of the German Audiology and Neurootology Group 2014 (ADANO) in Dresden/Germany No a...
Minerva is devoted to the study of ideas, traditions, cultures, and institutions in science, higher education, and research. It is equally focused on historical as well as present practices and on local as well as global issues. Moreover, the journal does not represent one single school of thought, but rather welcomes diversity within the rules of rational discourse.Esha Shah, Who is the Scientist-Subject? Affective History of the Gene Stress-Testing Europe: Normalizing the Post-Fukushima Crisis Abstract...
President's message K Sadashiva Shetty International Journal of Oral Health Sciences 2019 9(1):1-1 Secretary's message IM Ali Intern...
Otology & Neurotology - ACIA: Highlights from the 14th International Symposium on Cochlear Implants, Toronto, CanadaIntroduction to the 14th International Symposium on Cochlear Implants and other Implantable Auditory Technologies, Toronto, Canada, May 11 t...
Otology & Neurotology - Papers Presented at the Annual Meeting of the German Audiology and Neurotology Group 2016 (ADANO) in BerlinSpecial Issue of Audiology and Neurotology: Annual Autumn Meeting of the German Audiology & Neurotology Group (ADANO), Berlin October 19...
Otology & Neurotology - DOD Hearing Center of Excellence: Pharmaceutical Interventions for Hearing Loss (PIHL) Clinical Research Guidance PapersIntroduction to the Pharmaceutical Interventions for Hearing Loss Clinical Research Guidance Papers No abstract available The Genomic Basis ...
Otology & Neurotology - ACIA: Papers from the 14th Symposium on Cochlear Implants in Children, Nashville, TNIntroduction to the 14th Symposium on Cochlear Implants in Children, Nashville, TN Papers No abstract available Improving Spoken Language Ou...
Minimal-Invasive Robot-Assisted Image-Guided Resection of Prostate-Specific Membrane Antigen–Positive Lymph Nodes in Recurrent Prostate Canc...